Promising drug combo targets Tough-to-Treat lymphoma

NCT ID NCT04998669

Recruiting now Disease control Sponsor: Juan P. Alderuccio, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether a combination of two drugs—loncastuximab tesirine and rituximab—can shrink or eliminate tumors in people with follicular lymphoma that has come back or not responded to previous treatment. About 100 adults will receive the drugs through an IV over several cycles. The main goal is to see how many patients achieve a complete response (no signs of cancer) by week 12.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab tesirine (a drug that targets and kills cancer cells) combined with rituximab (an antibody therapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with follicular lymphoma that has come back or not responded to prior therapy.
What could go wrong: This is a Phase 2 trial with only 100 participants, so results are preliminary. The drug combination may cause side effects and might not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Allegheny Health Network
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15212, United States

Contact

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Florida Cancer Specialists and Research Institute
NOT_YET_RECRUITING

Fort Myers, Florida, 33916, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States

Contact Email: •••••@•••••

Contact
University of Miami
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Phone: •••-•••-••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.